Absci Corp

ABSI

2.695USD

+0.165+6.52%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Absci Corp's Score

Industry at a Glance

Industry Ranking

138 / 392

Overall Ranking

282 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Absci Corp Highlights

StrengthsRisks

Absci Corporation is a clinical-stage biopharmaceutical company advancing therapeutics with generative design. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. It has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.53M.

Fairly Valued

The company’s latest PE is -2.99, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 99.31M shares, increasing 0.03% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 7.91M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.61.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

8.046

Target Price

+218.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Absci Corp is 5.61, ranking 345 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 378.00K, representing a year-over-year decrease of 77.78%, while its net profit experienced a year-over-year decrease of 4.77%.

Score

Industry at a Glance

Previous score

5.61

Change

0



Financials

5.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.50

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.66

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Absci Corp is 5.92, ranking 354 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.99, which is -66.85% below the recent high of -0.99 and -108.10% above the recent low of -6.22.

Score

Industry at a Glance

Previous score

5.92

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 138/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Absci Corp is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 9.00, with a high of 10.00 and a low of 5.80.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Absci Corp is 6.90, ranking 139 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.31 and the support level at 2.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.64

Change

0.26

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Absci Corp is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 64.99%, representing a quarter-over-quarter decrease of 0.69%. The largest institutional shareholder is Catherine Wood, holding a total of 12.16M shares, representing 8.09% of shares outstanding, with 5.82% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

22.08M

+15.42%

ARK Investment Management LLC

Star Investors

12.16M

+21.07%

BlackRock Institutional Trust Company, N.A.

9.62M

+29.18%

McClain (Sean)

8.70M

-0.27%

Redmile Group, LLC

8.25M

--

The Vanguard Group, Inc.

Star Investors

7.28M

+12.87%

Phoenix Ventures Partners II LP.

4.75M

-49.28%

Columbia Threadneedle Investments (US)

3.19M

+1837.75%

Geode Capital Management, L.L.C.

3.05M

+24.84%

UBS Financial Services, Inc.

1.99M

+4.41%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Absci Corp is 3.27, ranking 158 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Absci Corp

ABSI

6.10 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment